Merck Portfolio Optimization: Strategic Reorganization for Enhanced Commercial Execution

By HEOR Staff Writer

February 24, 2026

Merck’s portfolio optimization strategy includes reorganizing its Human Health division into two focused business units—Oncology and Specialty, Pharma & Infectious Diseases—to sharpen commercial execution across its growing pipeline. This evolution appoints Jannie Oosthuizen to lead Oncology and MSD International, and Brian Foard to head Specialty, Pharma & Infectious Diseases, both reporting to CEO Robert M. Davis. The changes sustain oncology dominance while gearing up for over 20 blockbuster launches from roughly 80 Phase 3 studies, fueling long-term growth in key therapies.

Leadership Team

Jannie Oosthuizen, former senior vice president and president of Merck Human Health U.S., brings global marketing prowess and oncology commercialization wins to drive Merck portfolio optimization in this core area. Her expertise positions the unit for sustained market leadership amid pipeline expansion.

Brian Foard joins from Sanofi’s Specialty Care Business Unit, where he managed immunology, neurology, oncology, and rare diseases, plus nearly 20 years at Galderma in dermatology. His strategic depth bolsters the Specialty, Pharma & Infectious Diseases unit, aligning with broader Merck portfolio optimization goals.

Chirfi Guindo rises to executive vice president of Strategic Access, Policy & Communications, merging access, policy, sustainability, and stakeholder efforts. Drawing from commercial, international policy, and patient access experience, he ensures seamless U.S. and global alignment.

Pipeline Powerhouse with Blockbuster Potential

The structure supports Merck’s late-stage assets—around 80 Phase 3 trials eyeing more than 20 growth drivers, most with blockbuster upside. It tackles launch complexities in oncology and diversified areas like immunology and infectious diseases.

Reference url

Recent Posts

PSA Response Improvement: Promising Data from Pluvicto in mHSPC Treatment

By João L. Carapinha

May 19, 2026

New data from the PSMAddition study indicate that Pluvicto combined with standard of care, consisting of an androgen receptor pathway inhibitor plus androgen deprivation therapy, produced a 58% lower risk of prostate-specific antigen progression compared with standard of care alone. Patients rece...
Financing Boosts Vaccine Manufacturing Africa: New Facility to Enhance Local Production Capacity

By João L. Carapinha

In a major step forward for vaccine manufacturing Africa, Biovac has secured a financing package from the International Finance Corporation (IFC), the EIB Group, and the European Commission to build the continent’s first end-to-end multi-vaccine production facility. Landmark Funding ...
Enhertu Breast Cancer Treatment Gains FDA Approval in Neoadjuvant and Adjuvant Settings

By João L. Carapinha

May 18, 2026

Enhertu breast cancer treatment has secured FDA approval for neoadjuvant use in adults with HER2-positive Stage II or III disease before surgery, followed by taxane plus trastuzumab and pertuzumab, and for adjuvant therapy in patients with residual invasive disease after prior trastuzumab-based r...